Antibody Information
General Information of This Antibody
| Antibody ID | ANI0TOOQQ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Veltuzumab |
|||||
| Organization | Immunomedics, Inc.; Takeda Pharmaceutical Co., Ltd. |
|||||
| Indication | Non-Hodgkin's lymphoma |
|||||
| Synonyms |
HA20; IMMU-106; VELTUZUMAB
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | B-lymphocyte antigen CD20 (MS4A1) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| DrugBank ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSY
NQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSY
NQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVS S Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTSYN
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
IYPGMGDT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
ARSTYYGGDWYFDV
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVR
FSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVR
FSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
SSVSY
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
ATS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQWTSNPPT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Veltuzumab-SN-38 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.83 nM
|
Moderate CD20 expression (CD20++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Follicular lymphoma | WSU-FSCCL cells | CVCL_1903 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.98 nM
|
High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.88 nM
|
High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
13.56 nM
|
High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Daudi cells | CVCL_0008 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Childhood B acute lymphoblastic leukemia | 697 cells | CVCL_0079 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Adult B acute lymphoblastic leukemia | RS4;11 cells | CVCL_0093 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 50.00 nM | Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | Burkitt lymphoma | MN-60 cells | CVCL_1421 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
77.90 nM
|
Moderate CD22 expression (CD22++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
162 nM
|
Low CD20 expression (CD20+) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | B acute lymphoblastic leukemia | Reh cells | CVCL_1650 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
246.60 nM
|
High CD20 expression (CD20+++) | ||
| Method Description |
Cytotoxicity was determined using the MTS dye reduction assay.
|
||||
| In Vitro Model | EBV-related Burkitt lymphoma | Raji cells | CVCL_0511 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.